Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University Health Network, Toronto Princess Margaret Hospital, Canada |
---|---|
Information provided by: | University Health Network, Toronto |
ClinicalTrials.gov Identifier: | NCT00188877 |
Many normal tissues, including the eyes, brain, and spinal cord are very close to cancers in the nasopharynx. The dose of radiation delivered to the cancer is limited by tolerance of these normal tissues. Standard radiation treatment techniques using three or four radiation beams cannot avoid delivering some dose of radiation to these normal tissues that do not need to get radiation. Intensity Modulated Radiation Therapy (IMRT) uses many hundreds of computer-controlled radiation beams aimed at your cancer to try to lower the amount of radiation that normal tissues receive, while still delivering the desired amount of radiation to your cancer and to areas that your doctor thinks may have cancer cells.
The doctors at Princess Margaret Hospital are conducting this study in order to test whether the use of IMRT techniques can improve the chance of controlling your cancer in the head and neck region.
Condition | Intervention | Phase |
---|---|---|
Nasopharyngeal Neoplasms |
Procedure: intensity modulated radiation therapy Drug: cisplatinium and fluorouracil - standard treatment |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Study of Intensity Modulated Radiation Therapy for Nasopharyngeal Cancer |
Estimated Enrollment: | 44 |
Study Start Date: | June 2003 |
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria
Contact: Andrew Bayley, MD | 416-946-2919 | andrew.bayley@rmp.uhn.on.ca |
Canada, Ontario | |
Princess Margaret Hospital | Recruiting |
Toronto, Ontario, Canada, M5G 2M9 | |
Contact: Andrew Bayley, MD 416-946-2919 andrew.bayley@rmp.uhn.on.ca |
Principal Investigator: | Andrew Bayley, MD | Princess Margaret Hospital, Canada |
Study ID Numbers: | UHN REB 03-0158-C |
Study First Received: | September 12, 2005 |
Last Updated: | September 12, 2005 |
ClinicalTrials.gov Identifier: | NCT00188877 History of Changes |
Health Authority: | Canada: Ethics Review Committee |
Antimetabolites Nasopharyngeal Carcinoma Otorhinolaryngologic Diseases Otorhinolaryngologic Neoplasms Immunologic Factors Fluorouracil |
Head and Neck Neoplasms Pharyngeal Neoplasms Stomatognathic Diseases Immunosuppressive Agents Pharyngeal Diseases Nasopharyngeal Neoplasms |
Antimetabolites Otorhinolaryngologic Neoplasms Otorhinolaryngologic Diseases Antimetabolites, Antineoplastic Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Pharyngeal Neoplasms Immunosuppressive Agents |
Pharyngeal Diseases Pharmacologic Actions Nasopharyngeal Neoplasms Neoplasms Neoplasms by Site Therapeutic Uses Head and Neck Neoplasms Fluorouracil Nasopharyngeal Diseases Stomatognathic Diseases |